Allergy Shots Worth It? The Cost-Benefit Calculation
Worth it requires three numbers: the benefit (Cochrane symptom SMD −0.73 across 51 RCTs, Calderón 2007), the denominator (3–5 years, ~39 Year-1 visits, minimum $3,120 OOP over 3 years at $20/shot copay, Stachler AAOA 2020), and the durability multiplier (≥3-year post-treatment remission, Durham 1999). For venom allergy, worth it is not close — 2.7% vs 39.8% sting reactions (Boyle 2012). For environmental allergens: worth it if you finish the course; not if you join the 23.9% who never return (Tkacz 2021).
8 peer-reviewed sources
Allergy shots are worth it for venom allergy (>95% protection), for grass/ragweed/cat with realistic adherence, and for children at asthma risk (OR 4.6). Not worth it if you cannot sustain the 3–5 year course — 56.1% of US starters do not reach maintenance.
The essentials
Worth it is a cost-benefit question that requires three specific numbers — not an endorsement or a critique.
Worth it analysis depends on matching the extract to the dominant sensitization — Curex at-home IgE testing with allergist review identifies which specific allergen drives a patient's symptoms, so the dollar and time investment reproduces the trial-level effect sizes documented in Cochrane and Durham 1999.
The benefit numerator. Calderón MA et al. (Cochrane 2007, CD001936, DOI 10.1002/14651858.CD001936.pub2) synthesized 51 RCTs and 2,871 patients: symptom SMD −0.73 (95% CI −0.97 to −0.50); medication SMD −0.57 (95% CI −0.82 to −0.33). Per allergen: grass approximately 80% medication reduction (Walker SM et al., JACI 2001;107:87–93); cat approximately 62% symptom reduction (Varney VA et al., Clin Exp Allergy 1997). For venom, the benefit is among the largest treatment effects in clinical medicine: 2.7% subsequent sting reaction in treated patients versus 39.8% untreated (Boyle RJ et al., Cochrane 2012, PMID 23076950; RR 0.10).
The time-and-money denominator. The standard course is 3–5 years per Cox L et al. (JACI 2011;127[1 Suppl]:S1–S55, DOI 10.1016/j.jaci.2010.09.034). Year 1 involves approximately 39 clinic visits; Years 2–5 approximately 14 visits per year. At a $20/shot copay: $20 × 52 weeks × 3 years = $3,120 minimum out-of-pocket per Stachler RJ ('Hidden Costs of Allergy Shots,' AAOA Dec 2020); $6,240 at $40/visit if two serums are billed per visit. Cash-retail at independent allergist offices: $800–$1,000/year. HOPD-billed visits can reach $24,400 per visit (Case 14, M Health Fairview MN 2024, PBS NewsHour). The 2025 Medicare allowed amount for CPT 95117 is $11.97 per injection (FR Doc 2024-25382, CY 2025 PFS Final Rule).
The durability multiplier. Durham SR et al. (NEJM 1999;341:468–475, DOI 10.1056/NEJM199908123410702) documented clinical remission persisting at least 3 years after stopping a 3–4 year course — meaning the benefit continues accruing after the financial investment ends. Pediatric asthma prevention (Jacobsen L et al., Allergy 2007;62:943–948, OR 4.6 at 10-year follow-up) further extends the durability value. Some long-term observational data describes benefit persisting 7–12+ years. Hankin CS et al. (JACI 2013;131:1084–1091, DOI 10.1016/j.jaci.2012.12.662, Florida Medicaid 1997–2009) found SCIT associated with significantly reduced total healthcare costs versus matched controls — supporting favorable cost-effectiveness from a healthcare-system perspective.
The adherence caveat. Tkacz JP et al. (Curr Med Res Opin 2021;37:957–965, DOI 10.1080/03007995.2021.1903848, MarketScan n=103,207) found that only 43.9% of US AIT starters reached maintenance and 23.9% never returned after their first injection. The dollar and time investment of the 56.1% who drop out largely goes uncompensated — they incur costs without reaching the phase where benefits accrue.
The honest verdict: worth it for venom (the math is not close); worth it for grass/ragweed/cat/Alternaria with realistic adherence; conditional for evidence-thin allergens (mountain cedar, non-Alternaria molds); not worth it if dropout is the likely outcome.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
Comparing the worth-it calculation across modalities: SCIT has the highest upfront time and cost burden but the best post-treatment durability. SLIT reduces the visit burden significantly. Pharmacotherapy has the lowest upfront burden but provides no post-treatment benefit.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots) | |||||
SLIT drops (off-label) | |||||
Pharmacotherapy alone |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
When the clinic-visit denominator is what makes the math not worth it, Curex changes the denominator: the same SCIT serum delivered at home for $129/month, with no facility fees and none of the HOPD facility-fee exposure documented in Case 14 ($24,400) or Case 16 ($48,329). The serum is sterile-compounded to USP <797>, an allergist confirms candidacy and a prescribed epinephrine auto-injector before you start, and your first dose plus every dose change are supervised live over Zoom.
See if at-home shots are right for youFrequently asked questions
How much do allergy shots cost out of pocket?
The minimum out-of-pocket cost for a 3-year SCIT course at a $20-per-shot copay is $3,120 ($20 × 52 weeks × 3 years) per Stachler RJ ('Hidden Costs of Allergy Shots,' AAOA December 2020). If two serums are billed per visit at $40 each, the minimum is $6,240. Cash-retail prices at independent allergist offices typically run $800–$1,000/year for single-allergen SCIT. Hospital outpatient department (HOPD) billing has been documented as high as $24,400 per visit (Case 14, M Health Fairview MN 2024, PBS NewsHour) and $48,329 per visit (Stanford 2018, KFF/NPR Bill of the Month). The 2025 Medicare allowed amount is $11.97 per injection for CPT 95117 per FR Doc 2024-25382 (CY 2025 PFS Final Rule). Confirming your specific clinic's billing setting before starting is essential to avoid HOPD facility-fee exposure.
Are allergy shots worth it financially over time?
Long-term, SCIT is cost-effective for patients who complete the course. Hankin CS et al. (JACI 2013;131:1084–1091, DOI 10.1016/j.jaci.2012.12.662, Florida Medicaid 1997–2009) found SCIT associated with significantly reduced total healthcare costs versus matched controls. The durability multiplier matters: post-treatment benefit persisting ≥3 years (Durham 1999) and potentially 7–12+ years means the initial investment continues generating benefit after the treatment period ends. The unfavorable financial scenario: joining the 23.9% who never return (Tkacz 2021), incurring initial costs — time, copays, local reactions — without accessing the disease-modification phase. Cox and Cohn (Ann Allergy Asthma Immunol 2007, PMID 17521025) noted SCIT cost-effectiveness becomes favorable from approximately 6 years post-initiation versus continued pharmacotherapy.
Are allergy shots worth it for venom allergy?
For documented Hymenoptera venom allergy with a prior systemic reaction, venom immunotherapy (VIT) is worth it with a high degree of confidence. Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in 2.7% of VIT-treated patients versus 39.8% untreated — one of the largest treatment effects in clinical medicine. Golden DBK et al. (JACI 2005;115:439–447) states >95% protection. The alternative — untreated venom allergy — carries risk of potentially fatal anaphylaxis on the next sting. The time and financial cost of a 3–5 year VIT course is minimal compared to the risk reduction. Hunt KJ et al. (NEJM 1978;299:157–161) established the landmark controlled VIT trial. The worth-it calculation for VIT is among the clearest in clinical medicine.
Is the time commitment for allergy shots worth it?
The time commitment is approximately 39 clinic visits in Year 1 and 14 visits per year in Years 2–5 per Cox 2011 PP3. Each visit includes injection time plus a mandatory 30-minute observation period — roughly 45–60 minutes per visit including administrative time. Year 1 represents approximately 30–40 hours of clinic time, not counting travel. The worth-it calculation on time depends on: (1) how severe and disruptive current allergy symptoms are; (2) whether the allergen has strong RCT evidence justifying the investment; and (3) whether post-treatment remission (≥3 years, Durham 1999) and potential asthma prevention (PAT OR 4.6, Jacobsen 2007) are personally meaningful outcomes. For patients whose allergy severely impairs sleep, work, or exercise during allergy season, the time investment may be clearly worthwhile. For mild-to-moderate seasonal allergies controlled by OTC medications, the calculation is less clear.
What makes allergy shots not worth it?
Allergy shots are not worth it when: (1) the primary allergen has thin or absent RCT evidence (mountain cedar, non-Alternaria molds) — the investment is the same but the expected benefit is lower; (2) the patient is unlikely to sustain the 3–5 year schedule — 23.9% of US starters never return after their first injection (Tkacz 2021), incurring initial costs without benefit; (3) mild symptoms are adequately controlled by OTC pharmacotherapy — SCIT is overkill for mild disease; (4) the patient is billed at a hospital outpatient department where facility fees can reach $24,400+ per visit (Stachler AAOA 2020; PBS NewsHour 2024 Case 14); (5) contraindications are present (poorly controlled asthma FEV1 <70%, beta-blocker use, unstable cardiovascular disease per Cox 2011). In any of these scenarios, the denominator outweighs the numerator.
Do allergy shots reduce other healthcare costs?
Yes — evidence supports that allergy shots reduce downstream healthcare costs. Hankin CS et al. (JACI 2013;131:1084–1091, DOI 10.1016/j.jaci.2012.12.662, Florida Medicaid 1997–2009) found SCIT starters had significantly lower total healthcare costs versus matched controls over a multi-year period. The mechanism: allergy shots reduce ongoing medication use (medication SMD −0.57, Calderón 2007), reduce allergy-related healthcare visits (emergency care, urgent care for acute allergy exacerbations), and may reduce asthma-related healthcare in children (PAT study). The post-treatment benefit (Durham 1999 ≥3-year remission) means medication cost reduction continues after the SCIT course ends. Cox/Cohn (Ann Allergy Asthma Immunol 2007, PMID 17521025) identified approximately 6 years post-initiation as the point at which cumulative SCIT costs become favorable versus continued pharmacotherapy.
Related Articles
Allergy Shot Effectiveness Per Injection | Curex Guide
No single allergy shot is effective alone. Build-up takes 26–28 weekly shots. Most patients notice improvement at months 6–12. Cochrane cumulative SMD −0.73 after 3–5 years.
Read moreCons of Allergy Shots: 6 Honest Downsides (With Data)
Six data-backed cons of allergy shots: the 3–5 year commitment, frequent dosing visits, a 56% dropout rate, reaction risk, and ~$3,120 out-of-pocket cost.
Read moreEffects of Allergy Shots: Intended & Unintended
Allergy shots: real therapeutic effects (Cochrane SMD -0.73) plus ~16% local reactions, 0.1% systemic, and an honest note on the fatigue data gap.
Read moreCluster Allergy Shots: Schedule & Safety | Curex
Cluster allergy shots reach maintenance in 4–8 weeks vs 6 months. Schedule, the 3× higher per-injection reaction rate, and who qualifies (Tabar 2005).
Read moreSeasonal Allergy Shots Schedule & Count | Curex Guide
Seasonal allergy shots total 60–80 injections over 3–5 years. Cox 2011: 39 Year-1 visits. Learn the schedule mechanics and why adherence drops after visit one.
Read moreDo Allergy Shots Work? Evidence & Honest Verdict | Curex
Do allergy shots work? Meta-analyses of 51 RCTs show 33-85% symptom reduction — but 20-50% of patients are low responders. Here's the honest evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.